In:
Retina, Ovid Technologies (Wolters Kluwer Health), Vol. 38, No. 5 ( 2018-05), p. 993-999
Abstract:
To investigate the efficacy and safety of intraoperative slow-release dexamethasone implant and 25-gauge (G) vitrectomy plus epiretinal membrane removal in patients affected by idiopathic macular pucker. Methods: In this randomized, clinical, multicenter study, 60 eyes of 60 pseudophakic eyes having idiopathic macular pucker were enrolled. Thirty eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling (“Control group”), whereas 30 eyes underwent 25-G pars plana vitrectomy and internal limiting membrane peeling combined with dexamethasone implant (“DEX group”). Best-corrected visual acuity was investigated using Snellen visual acuity ratio. Anatomical outcomes (foveal thickness and total macular volume) were analyzed with spectral domain optical coherence tomography. Results: After 6-month follow-up, best-corrected visual acuity significantly increased in each group ( P 〈 0.05), but there were no significant differences between groups ( P = 0.60). Foveal thickness showed a significant decrease in both groups ( P 〈 0.05), but no differences were seen between groups ( P = 0.80). Finally, also total macular volume decreased significantly in both groups at the last follow-up visit ( P 〈 0.05), but both groups a showed similar trend ( P = 0.12). Conclusions: Intraoperative sustained-release dexamethasone implant, a powerful antiinflammatory agent with significant efficacy in vitrectomized eyes, did not result in a significant change in macular thickness and volume compared with the vitrectomy alone without dexamethasone implant at 6-month follow-up. These data support the hypothesis that its etiology does not seem to be mainly related to an inflammatory process.
Type of Medium:
Online Resource
ISSN:
0275-004X
DOI:
10.1097/IAE.0000000000001627
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2018
detail.hit.zdb_id:
2071014-8
Bookmarklink